Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 14Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Hematologic Neoplasms 10Recurrence 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Hematologic Diseases 3Philadelphia Chromosome 2Neoplasms 2Myeloproliferative Disorders 2Mastocytosis, Systemic 2Lymphoproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Mast-Cell 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Glioma 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Bone Marrow Diseases 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Waldenstrom Macroglobulinemia 1

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Anemia × Other hematologic neoplasm × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡